4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide and Leukemia--Prolymphocytic--B-Cell

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide has been researched along with Leukemia--Prolymphocytic--B-Cell* in 1 studies

Trials

1 trial(s) available for 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide and Leukemia--Prolymphocytic--B-Cell

ArticleYear
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
    American journal of hematology, 2019, Volume: 94, Issue:4

    Topics: Aged; Female; Hematologic Neoplasms; Humans; Janus Kinases; Leukemia, Prolymphocytic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Pyrimidines; Sulfones; Syk Kinase

2019